Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study

Adrienn Zsippai1, Diana Rita Szabó, Zsófia Tömböl

  • 12nd Department of Medicine, Faculty of Medicine, Semmelweis University, Szentkirályi street 46, H-1088 Budapest, Hungary.

Pharmacogenomics
|September 13, 2012
PubMed
Abstract

Insights

Mitotane, used for adrenocortical cancer, alters gene expression in adrenal cells. This study identifies specific genes involved in steroid hormone biosynthesis and other functions, shedding light on mitotane's mechanism of action.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Mitotane is a key treatment for adrenocortical cancer.
  • Its precise mechanism of action remains unclear.
  • Understanding mitotane's effects on gene expression is crucial.

Purpose of the Study:

  • To investigate mitotane-induced changes in mRNA expression.
  • To identify genes affected by mitotane in an adrenocortical cancer cell line.
  • To elucidate the molecular mechanisms underlying mitotane's therapeutic effects.

Main Methods:

  • Utilized the NCI-H295R adrenocortical cancer cell line.
  • Employed microarray analysis (Agilent 4×44K) to assess gene expression.
  • Validated key findings using quantitative reverse-transcription PCR.

Main Results:

  • Identified 117 differentially expressed genes in mitotane-treated cells.
  • Validated underexpression of steroid hormone biosynthesis genes (HSD3B1, HSD3B2, CYP21A2).
  • Validated overexpression of genes including GDF15, ALDH1L2, TRIB3, and SERPINE2.

Conclusions:

  • Mitotane significantly alters gene expression profiles in adrenocortical cancer cells.
  • Observed gene expression changes correlate with mitotane's known effects on hormone secretion.
  • These findings provide insights into the molecular basis of mitotane's action.